Skip to main content
. 2021 Apr 15;11:631594. doi: 10.3389/fonc.2021.631594

Figure 4.

Figure 4

Carfilzomib does not extend survival in infant KMT2A-rearranged acute lymphoblastic leukemia xenografts. (A, B) Kaplan-Meier survival curves of mice injected with PER-785 or PER-826 leukemia cells that were treated at low leukemic burden with vehicle control or 2 mg/kg carfilzomib on days 1, 2, 8, 9, 15, and 16 (n = 8 mice per group). (C, D) Kaplan-Meier survival curves of mice injected with MLL-5 or MLL-14 leukemia cells that were treated at high leukemic burden with carfilzomib, VXL, carfilzomib-VXL combination therapy, or vehicle control (n = 10 mice per group). Carfilzomib was administered intravenously on days 1, 2, 8, 9, 15, and 16 at 1.5 mg/kg. VXL comprised of 0.15 mg/kg of vincristine once a week for 4 weeks, dexamethasone 5 mg/kg 5 days a week for 4 weeks, and L-asparaginase 1,000 U/kg 5 days a week for 4 weeks, administered by intraperitoneal injection. Gray shaded areas indicate treatment duration, with the first dotted line representing the start of therapy and the second dotted line the end of therapy. *P < 0.05, **P < 0.001, ***P < 0.0001.